2Ferrara J, Antin J. Thomas Hematopoietic cell transplantation [M]. 4th ed. Malden: Wiley-Blackwell Publishing l,td, 2009: 353-368.
3Harris A C, Ferrara J I., Levine J E. Advances in predicting acuteGVHD [J]. BrJ Haematol, 2013, 160 (3): 288-302.
4Blazar BR, Murphy W J, Abedi M. Advances in graft-versus-host disease biology and therapy [J]. Nat Rev Immunol, 2012 12 (6) : 443-458.
5Inamoto Y, Flowers M E, Lee S J, et al. Influence of immuno- suppressive treatment on risk of recurrent malignancy after allo- geneic hematopoietic cell transplantation [J].Blood, 2011, 118 (2): 456-463.
6Carpenter P A, Lowder J, Johnston L, et al. A phase II multi- center study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease [J]. Biol Blood Marrow Transplant, 2005, 11 (6) : 465-471.
7Li X, Deng R, He W, et al. Loss of B7-H1 expression by re- cipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease [J]. J Immunol, 2012, 188 (2): 724-734.
8He W, Racine J J, Johnston H F, et al, Depletion of host CCR7 (+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients [J]. Biol Blood Marrow Transplant, 2014, 20 (7): 920-928.
9Li N, Chen Y, He W, et al. Anti-CD3 preconditioning sepa- rates GVL from GVHD via modulating host dendritic cell anddonor T-cell migration in recipients conditioned with TBI [J]. Blood, 2009, 113 (4): 953-962.
10Li N, Zhao D, Kirschhaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of ehimerism that rever- ses lupus in anti-CD3 conditioning regimen [J]. Proc Natl Acad SciUSA, 2008, 105 (12): 4796-4801.
